Back to top
more

ImmunityBio (IBRX)

(Delayed Data from NSDQ)

$5.79 USD

5.79
1,761,321

-0.19 (-3.18%)

Updated Jul 19, 2024 04:00 PM ET

After-Market: $5.80 +0.01 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for IBRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for ImmunityBio, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 266 107 317 66 52
Receivables 0 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 28 33 17 9 4
Total Current Assets 294 141 334 76 56
Net Property & Equipment 146 144 83 54 61
Investments & Advances 1 6 1 8 11
Other Non-Current Assets 7 7 6 0 0
Deferred Charges 0 0 0 0 0
Intangibles 17 20 1 0 0
Deposits & Other Assets 3 0 7 1 4
Total Assets 504 362 469 152 143
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 432 299 0 0
Accounts Payable 9 21 11 4 2
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 43 42 51 8 5
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 1 3 4 7 4
Total Current Liabilities 58 501 369 25 12
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 577 0 0 0 0
Long-Term Debt 105 241 306 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 311 22 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,090 812 713 34 22
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 2,375 1,931 1,720 872 783
Retained Earnings -2,962 -2,378 -1,962 -755 -662
Other Equity 1 -2 -2 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -586 -450 -244 117 121
Total Liabilities & Shareholder's Equity 504 362 469 152 143
Total Common Equity -586 -450 -244 117 121
Shares Outstanding 667.70 400.30 397.60 109.00 98.30
Book Value Per Share -0.88 -1.12 -0.61 1.08 1.23

Fiscal Year End for ImmunityBio, Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 171 266 190 46
Receivables NA 0 0 0 0
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 25 28 25 21
Total Current Assets NA 196 294 215 67
Net Property & Equipment NA 144 146 152 151
Investments & Advances NA 0 1 1 1
Other Non-Current Assets NA 7 7 7 7
Deferred Charges NA 0 0 0 0
Intangibles NA 17 17 18 19
Deposits & Other Assets NA 3 3 3 4
Total Assets NA 401 504 432 291
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 0 0 37
Accounts Payable NA 14 9 20 25
Current Portion Long-Term Debt NA 0 0 0 482
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 33 43 65 62
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 1 1 1 1
Total Current Liabilities NA 54 58 90 613
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 577 28 0
Long-Term Debt NA 687 105 645 250
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 311 40 28
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,092 1,090 843 936
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 2,404 2,375 2,316 1,991
Retained Earnings NA -3,096 -2,962 -2,728 -2,633
Other Equity NA 1 1 2 -3
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA -691 -586 -411 -645
Total Liabilities & Shareholder's Equity NA 401 504 432 291
Total Common Equity 0 -691 -586 -411 -645
Shares Outstanding 691.50 677.00 667.70 667.70 440.60
Book Value Per Share 0.00 -1.02 -0.88 -0.62 -1.46